acumapimod   Click here for help

GtoPdb Ligand ID: 9203

Synonyms: BCT 197 | BCT-197 | BCT197 | compound A [WO2013139809]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Acumapimod (BCT-197) is an orally active p38 mitogen activated protein kinase inhibitor with potential anti-inflammatory action. This compound is claimed in patent WO2013139809 [1] and in patent WO2005009973 as EXAMPLE 52 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 113.28
Molecular weight 385.15
XLogP 3.64
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1cccc(c1)C(=O)c1cnn(c1N)c1cc(ccc1C)C(=O)NC1CC1
Isomeric SMILES N#Cc1cccc(c1)C(=O)c1cnn(c1N)c1cc(ccc1C)C(=O)NC1CC1
InChI InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29)
No information available.
Summary of Clinical Use Click here for help
Acumapimod is being evaluated in Phase 2 clinical trial (NCT02700919) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The p38 mitogen-activated protein kinase is a key signaling pathway involved in regulation of inflammatory cytokines.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02700919 Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Phase 2 Interventional Mereo BioPharma